Xiaobo Yang

Dr. Xiaobo Yang


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2014 in Critical Care
Verified
Journal Article
Open access
PDF file
XYXiaobo Yang
Xiaobo Yang
BDBin Du
Bin Du
Introduction: Fluid resuscitation is crucial in managing hemodynamically unstable patients. The last decade witnessed the use of pulse pressure variation (PPV) to predict fluid responsiveness. However, as far as we know, no systematic review and meta-analysis has been carried out to evaluate the value of PPV in predicting fluid responsiveness specifically upon patients admitted into intensive care units. Methods: We searched MEDLINE and EMBASE and included clinical trials that evaluated the association between PPV and fluid responsiveness after fluid challenge in mechanically ventilated patients in intensive care units. Data were synthesized using an exact binomial rendition of the bivariate mixed-effects regression model modified for synthesis of diagnostic test data. Result: Twenty-two studies with 807 mechanically ventilated patients with tidal volume more than 8 ml/kg and without spontaneous breathing and cardiac arrhythmia were included, and 465 were responders (58%). The pooled sensitivity was 0.88 (95% confidence interval (CI) 0.81 to 0.92) and pooled specificity was 0.89 (95% CI 0.84 to 0.92). A summary receiver operating characteristic curve yielded an area under the curve of 0.94 (95% CI 0.91 to 0.95). A significant threshold effect was identified. Conclusions: PPV predicts fluid responsiveness accurately in mechanically ventilated patients with relative large tidal volume and without spontaneous breathing and cardiac arrhythmia.

4 December 2023 in Critical Care
Verified
Journal Article
Open access
PDF file
YTYun Tang
Yun Tang
XGXuehui Gao
Xuehui Gao
JXJiqian Xu
Jiqian Xu
LRLehao Ren
Lehao Ren
HQHong Qi
Hong Qi
YSYou Shang
You Shang
Objective: To compare the efficacy and safety of remimazolam besylate and propofol for deep sedation in critically ill patients. Methods: In this single-center, prospective, randomized, controlled pilot study, patients in the intensive care unit (ICU) requiring deep sedation were randomized to receive remimazolam besylate or propofol intravenously. Deep sedation was defined as a Richmond Agitation and Sedation Scale (RASS) score of − 4 or − 5. Sedation depth was monitored using RASS and Narcotrend Index (NI). The primary outcome was the percentage of time within the target sedation range without rescue sedation. The secondary outcomes included ventilator-free hours within 7 days, successful extubation, length of ICU stay, and 28-day mortality. Adverse events during the interventional period were also recorded. Results: Thirty patients were assigned to each group. The median (IQR) RASS score was − 5.0 (− 5.0, − 4.0), and the median (IQR) NI value was 29.0 (21.0, 37.0) during the intervention period. Target RASS was reached a median of 100% of the sedation time in the two groups. No significant differences were observed in ventilator-free hours within 7 days, successful extubation, length of ICU stay, or 28-day mortality among groups. Hypotension occurred in 16 (53.3%) patients of remimazolam group and 18 (60.0%) patients of propofol group (p > 0.05). No patient experienced bradycardia. Conclusions: Remimazolam besylate appears to be an effective and safe agent for short-term deep sedation in critically ill patients. Our findings warrant large sample-sized randomized clinical trials.

1 October 2019 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
XYXiaobo Yang
Xiaobo Yang
YSYou Shang
You Shang
SYShiying Yuan
Shiying Yuan
Background: Data on the safety and feasibility of pulse oxygen saturation (SpO2) directed oxygen therapy in mainland China are scarce. The aim of this pilot study was to test the feasibility of SpO2 directed oxygen therapy and to calculate sample size base on differences in 28-day mortality rates for a large sample-sized randomized trial. Methods: This prospective pilot study enrolled 214 adult patients with an expected intensive care unit (ICU) stay of more than 72 hours. Patients were randomized into a low SpO2 group (SpO2 90–95%) or high SpO2 group (SpO2 96–100%). The primary outcome was 28-day mortality. Results: One hundred patients were included in the low SpO2 group, and 114 patients were included in the high SpO2 group. The demographic and baseline characteristics were not different. The time-weighted SpO2 average was significantly lower in the low SpO2 group than in the high SpO2 group [mean ± standard deviation (SD), 95.7%±2.3% vs. 98.2%±1.8%, P<0.001]. Twenty-six patients (26%) in the low SpO2 group died within 28 days after inclusion, while 37 patients (32.5%) in the high SpO2 group died (P=0.301). The time to death within 28 days between the two groups was not different (P=0.284). Conclusions: SpO2 directed oxygen therapy in critically ill patients was feasible. Our pilot trial necessitates and rationalizes our large-sample multicenter trial.

23 December 2020 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
CWChong Wang
Chong Wang
JXJiqian Xu
Jiqian Xu
SWShaoyuan Wang
Shaoyuan Wang
SPShangwen Pan
Shangwen Pan
JZJiancheng Zhang
Jiancheng Zhang
YSYou Shang
You Shang
SARS-coronavirus-2–induced immune dysregulation and inflammatory responses are involved in the pathogenesis of coronavirus disease-2019 (COVID-19). However, very little is known about immune cell and cytokine alterations in specific organs of COVID-19 patients. Here, we evaluated immune cells and cytokines in postmortem tissues, i.e., lungs, intestine, liver, kidneys, and spleen of three patients with COVID-19. Imaging mass cytometry revealed monocyte, macrophage, and dendritic cell (DC) infiltration in the lung, intestine, kidney, and liver tissues. Moreover, in patients with COVID-19, natural killer T cells infiltrated the liver, lungs, and intestine, whereas B cells infiltrated the kidneys, lungs, and intestine. CD11b+ macrophages and CD11c+ DCs also infiltrated the lungs and intestine, a phenomenon that was accompanied by overproduction of the immunosuppressive cytokine interleukin (IL)-10. However, CD11b+ macrophages and CD11c+ DCs in the lungs or intestine of COVID-19 patients did not express human leukocyte antigen DR isotype. In contrast, tumor necrosis factor (TNF)-α expression was higher in the lungs, intestine, liver, and kidneys, but not in the spleen, of all COVID-19 patients (compared to levels in controls). Collectively, these findings suggested that IL-10 and TNF-α as immunosuppressive and pro-inflammatory agents, respectively,—might be prognostic and could serve as therapeutic targets for COVID-19.


19 April 2017 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
YSYao Shi
Yao Shi
HJHong Jiang
Hong Jiang
XYXiaobo Yang
Xiaobo Yang
The aim of the present study was to investigate the protective effect of the selective peroxisome proliferator-activated receptor δ (PPARδ) agonist GW501516 (GW) on lipopolysaccharide (LPS)‑induced apoptosis in the rat cardiomyoblast cell line H9c2, and to investigate the possible underlying mechanisms. Cell viability was estimated using the MTT assay. Apoptosis was estimated by flow cytometry using Annexin V‑fluorescein isothiocyanate/propidium iodide staining and caspase‑3 activity assay. The protein level of heme oxygenase‑1 (HO‑1), cleaved caspase‑3 (CC3), apoptosis regulator Bcl‑2 (bcl‑2), apoptosis regulator BAX (bax) and nuclear factor‑κB (NF‑κB) p65 was measured by western blot analysis. The results demonstrated that pretreatment with GW inhibited the LPS‑induced increase in the rate of apoptosis. Pretreatment with GW also increased the bcl‑2/bax ratio, and decreased CC3 protein expression as well as caspase‑3 activity, in LPS‑stimulated H9c2 cells. Further studies demonstrated that GW inhibited LPS‑induced NF‑κB nuclear translocation in a dose‑dependent manner. In addition, GW induced HO‑1 protein expression in a dose‑dependent manner. ZnPP‑IX, an inhibitor of HO‑1, reversed the inhibitory effect of GW on LPS‑induced NF‑κB activation, leading to the attenuation of PPARδ‑mediated apoptosis resistance. In conclusion, these results suggest that PPARδ activation exerts an anti‑apoptotic effect in LPS‑stimulated H9c2 cardiomyoblasts, potentially through heme oxygenase‑1‑mediated suppression of NF‑κB activation. PPARδ appears to be a promising therapeutic target for the treatment of sepsis‑associated cardiac dysfunction.